Cliff Asness’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.18M | Buy |
1,296,684
+537,192
| +71% | +$781K | ﹤0.01% | 2566 |
|
|
2026
Q1 | $1M | Buy |
759,492
+672,528
| +773% | +$1.2M | ﹤0.01% | 2771 |
|
|
2025
Q4 | $163K | Buy |
86,964
+35,629
| +69% | +$68.5K | ﹤0.01% | 3401 |
|
|
2025
Q3 | $65.7K | Buy |
51,335
+34,346
| +202% | +$46.5K | ﹤0.01% | 3406 |
|
|
2025
Q2 | $21.1K | Buy |
16,989
+6,067
| +56% | +$7.01K | ﹤0.01% | 3278 |
|
|
2025
Q1 | $12.9K | Buy |
+10,922
| New | +$16.8K | ﹤0.01% | 3140 |
|
|
2024
Q2 | – | Sell |
-108,364
| Closed | -$406K | – | 2657 |
|
|
2024
Q1 | $406K | Buy |
108,364
+36,274
| +50% | +$212K | ﹤0.01% | 2033 |
|
|
2023
Q4 | $707K | Buy |
72,090
+33,837
| +88% | +$277K | ﹤0.01% | 1736 |
|
|
2023
Q3 | $319K | Buy |
38,253
+4,510
| +13% | +$51.5K | ﹤0.01% | 1993 |
|
|
2023
Q2 | $449K | Buy |
33,743
+17,519
| +108% | +$213K | ﹤0.01% | 1823 |
|
|
2023
Q1 | $188K | Buy |
+16,224
| New | +$161K | ﹤0.01% | 2060 |
|
|
2022
Q1 | – | Sell |
-62,416
| Closed | -$1.28M | – | 2270 |
|
|
2021
Q4 | $1.28M | Sell |
62,416
-75,003
| -55% | -$1.81M | ﹤0.01% | 1427 |
|
|
2021
Q3 | $3.51M | Buy |
137,419
+13,061
| +11% | +$387K | 0.01% | 909 |
|
|
2021
Q2 | $4.35M | Sell |
124,358
-35,423
| -22% | -$1.03M | 0.01% | 870 |
|
|
2021
Q1 | $5.32M | Sell |
159,781
-26,258
| -14% | -$919K | 0.01% | 813 |
|
|
2020
Q4 | $4.83M | Buy |
186,039
+63,370
| +52% | +$1.08M | 0.01% | 795 |
|
|
2020
Q3 | $1.21M | Sell |
122,669
-31,445
| -20% | -$181K | ﹤0.01% | 1325 |
|
|
2020
Q2 | $532K | Buy |
+154,114
| New | +$525K | ﹤0.01% | 1719 |
|
|
2017
Q1 | – | Sell |
-50,029
| Closed | -$190K | – | 2233 |
|
|
2016
Q4 | $190K | Sell |
50,029
-73,760
| -60% | -$536K | ﹤0.01% | 2158 |
|
|
2016
Q3 | $1.11M | Sell |
123,789
-72,391
| -37% | -$605K | ﹤0.01% | 1688 |
|
|
2016
Q2 | $1.38M | Buy |
196,180
+45,444
| +30% | +$415K | ﹤0.01% | 1484 |
|
|
2016
Q1 | $1.28M | Buy |
+150,736
| New | +$1.48M | ﹤0.01% | 1475 |
|
|
2015
Q4 | – | Sell |
-51,323
| Closed | -$188K | – | 2287 |
|
|
2015
Q3 | $188K | Sell |
51,323
-20,949
| -29% | -$102K | ﹤0.01% | 2072 |
|
|
2015
Q2 | $416K | Sell |
72,272
-37,382
| -34% | -$216K | ﹤0.01% | 1855 |
|
|
2015
Q1 | $641K | Sell |
109,654
-36,500
| -25% | -$252K | ﹤0.01% | 1604 |
|
|
2014
Q4 | $1.15M | Sell |
146,154
-5,840
| -4% | -$37.4K | ﹤0.01% | 1581 |
|
|
2014
Q3 | $746K | Buy |
151,994
+59,200
| +64% | +$310K | ﹤0.01% | 1761 |
|
|
2014
Q2 | $573K | Hold |
92,794
| – | – | ﹤0.01% | 1925 |
|
|
2014
Q1 | $496K | Buy |
92,794
+1,300
| +1% | +$8.22K | ﹤0.01% | 2048 |
|
|
2013
Q4 | $479K | Buy |
91,494
+78,594
| +609% | +$361K | ﹤0.01% | 2089 |
|
|
2013
Q3 | $71K | Buy |
+12,900
| New | +$44.8K | ﹤0.01% | 2450 |
|
Other funds holding PACB
AIM
NAMA
Cliff Asness's PACB Position: Q2 2026 in Review
Cliff Asness increased its Pacific Biosciences (PACB) stake by 71% in Q2 2026, buying an estimated $781K and bringing the position to 1,296,684 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2566.
Cliff Asness first reported a position in PACB in Q3 2013 and has held it in 31 quarters since. The position peaked at $5.32M in Q1 2021. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Cliff Asness held 1,296,684 shares of Pacific Biosciences worth $2.18M as of Q2 2026.
- Cliff Asness bought 537,192 Pacific Biosciences shares in Q2 2026, an estimated $781K.
- Pacific Biosciences made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2566 holding.
- Cliff Asness first reported a position in Pacific Biosciences in Q3 2013 and has held it in 31 quarters since.
- Cliff Asness's Pacific Biosciences position peaked at $5.32M in Q1 2021.
- 222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.